NA
CBAY

Neuburgh Advisers’s Cymabay Therapeutics CBAY Stock Holding History

Neuburgh Advisers’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$9K Hold
1,738
– – ﹤0.01% 912
2019
Q2 		$12K Hold
1,738
– – ﹤0.01% 900
2019
Q1 		$23K Hold
1,738
– – ﹤0.01% 883
2018
Q4 		$14K Buy
+1,738
New +$16.5K ﹤0.01% 875

Other funds holding CBAY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Neuburgh Advisers's CBAY Position: Q3 2019 in Review

Neuburgh Advisers held its Cymabay Therapeutics (CBAY) position steady in Q3 2019 at 1,738 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #912.

Neuburgh Advisers first reported a position in CBAY in Q4 2018 and has held it in 4 quarters since. The position peaked at $23K in Q1 2019. 137 funds tracked by Wall St. Rank hold CBAY as of Q3 2019.

  • Neuburgh Advisers held 1,738 shares of Cymabay Therapeutics worth $9K as of Q3 2019.
  • Neuburgh Advisers left its Cymabay Therapeutics share count unchanged in Q3 2019.
  • Cymabay Therapeutics made up ﹤0.01% of Neuburgh Advisers's portfolio in Q3 2019, its #912 holding.
  • Neuburgh Advisers first reported a position in Cymabay Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Neuburgh Advisers's Cymabay Therapeutics position peaked at $23K in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2019.

Based on Neuburgh Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.